Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Brian Feldman and Victor Blanchette.
|
|
Connection Strength |
|
 |
|
 |
|
4.155 |
|
|
|
-
Feldman BM, Rivard GE, Babyn P, Wu JKM, Steele M, Poon MC, Card RT, Israels SJ, Laferriere N, Gill K, Chan AK, Carcao M, Klaassen RJ, Cloutier S, Price VE, Dover S, Blanchette VS. Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort. Lancet Haematol. 2018 Jun; 5(6):e252-e260.
Score: 0.828
-
Feldman BM, Funk SM, Bergstrom BM, Zourikian N, Hilliard P, van der Net J, Engelbert R, Petrini P, van den Berg HM, Manco-Johnson MJ, Rivard GE, Abad A, Blanchette VS. Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: validity of the hemophilia joint health score. Arthritis Care Res (Hoboken). 2011 Feb; 63(2):223-30.
Score: 0.501
-
Feldman BM, Babyn P, Doria AS, Heijnen L, Jacobson J, Kilcoyne R, Lundin B, Manco-Johnson M, McLimont M, Petrini P, Pettersson H, Blanchette VS. Proceedings of the International Haemophilia Prophylaxis Study Group Meeting, November 2003, Montreal, PQ, Canada. Haemophilia. 2005 Jan; 11(1):58-63.
Score: 0.329
-
Dover S, Blanchette VS, Srivastava A, Fischer K, Abad A, Feldman BM. Clinical outcomes in hemophilia: Towards development of a core set of standardized outcome measures for research. Res Pract Thromb Haemost. 2020 May; 4(4):652-658.
Score: 0.237
-
Dover S, Blanchette VS, Wrathall D, Pullenayegum E, Kazandjian D, Song B, Hawes SA, Cloutier S, Rivard GE, Klaassen RJ, Paradis E, Laferriere N, Stain AM, Chan AK, Israels SJ, Sinha R, Steele M, Wu JKM, Feldman BM. Hemophilia prophylaxis adherence and bleeding using a tailored, frequency-escalated approach: The Canadian Hemophilia Primary Prophylaxis Study. Res Pract Thromb Haemost. 2020 Feb; 4(2):318-325.
Score: 0.234
-
Crivianu-Gaita V, Rivard GE, Carcao M, Teitel J, St-Louis J, Blanchette V, Pullenayegum E, Abad A, Feldman BM. Pilot study of once-a-day prophylaxis for youth and young adults with severe haemophilia A. Haemophilia. 2016 Sep; 22(5):e401-5.
Score: 0.183
-
Langley AR, Stain AM, Chan A, McLimont M, Chait S, Wu J, Poon MC, Card R, Israels SJ, Laferriere N, Klaassen RJ, Rivard GE, Cloutier S, Hawes S, Feldman B, Blanchette V. Experience with central venous access devices (CVADs) in the Canadian hemophilia primary prophylaxis study (CHPS). Haemophilia. 2015 Jul; 21(4):469-76.
Score: 0.170
-
Hilliard P, Zourikian N, Blanchette V, Chan A, Elliott B, Israels SJ, Nilson J, Poon MC, Laferriere N, Van Neste C, Jarock C, Wu J, McLimont M, Feldman B. Musculoskeletal health of subjects with hemophilia A treated with tailored prophylaxis: Canadian Hemophilia Primary Prophylaxis (CHPS) Study. J Thromb Haemost. 2013 Mar; 11(3):460-6.
Score: 0.145
-
Feldman BM, Funk S, Lundin B, Doria AS, Ljung R, Blanchette V. Musculoskeletal measurement tools from the International Prophylaxis Study Group (IPSG). Haemophilia. 2008 Jul; 14 Suppl 3:162-9.
Score: 0.105
-
Risebrough N, Oh P, Blanchette V, Curtin J, Hitzler J, Feldman BM. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A. Haemophilia. 2008 Jul; 14(4):743-52.
Score: 0.103
-
Feldman BM, Aledort L, Bullinger M, Delaney FM, Doria AS, Funk S, Giangrande P, Lundin B, Manco-Johnson M, Miners A, Scriba PC, Srivastava A, Schramm W, Blanchette VS. The economics of haemophilia prophylaxis: governmental and insurer perspectives. Proceedings of the Second International Prophylaxis Study Group (IPSG) symposium. Haemophilia. 2007 Nov; 13(6):745-9.
Score: 0.099
-
Ota S, Mclimont M, Carcao MD, Blanchette VS, Graham N, Paradis E, Feldman BM. Definitions for haemophilia prophylaxis and its outcomes: the Canadian consensus study. Haemophilia. 2007 Jan; 13(1):12-20.
Score: 0.094
-
Feldman BM, Pai M, Rivard GE, Israels S, Poon MC, Demers C, Robinson S, Luke KH, Wu JK, Gill K, Lillicrap D, Babyn P, McLimont M, Blanchette VS. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost. 2006 Jun; 4(6):1228-36.
Score: 0.091
-
Kern M, Blanchette V, Stain AM, Einarson TR, Feldman BM. Clinical and cost implications of target joints in Canadian boys with severe hemophilia A. J Pediatr. 2004 Nov; 145(5):628-34.
Score: 0.081
-
Manco-Johnson MJ, Pettersson H, Petrini P, Babyn PS, Bergstrom BM, Bradley CS, Doria AS, Feldman BM, Funk S, Hilliard P, Kilcoyne R, Lundin B, Nuss R, Rivard G, Schoenmakers MA, Van den Berg M, Wiedel J, Zourikian N, Blanchette VS. Physical therapy and imaging outcome measures in a haemophilia population treated with factor prophylaxis: current status and future directions. Haemophilia. 2004 Oct; 10 Suppl 4:88-93.
Score: 0.081
-
Revel-Vilk S, Golomb MR, Achonu C, Stain AM, Armstrong D, Barnes MA, Anderson P, Logan WJ, Sung L, McNeely M, Blanchette V, Feldman BM. Effect of intracranial bleeds on the health and quality of life of boys with hemophilia. J Pediatr. 2004 Apr; 144(4):490-5.
Score: 0.078
-
Brunner HI, Maker D, Grundland B, Young NL, Blanchette V, Stain AM, Feldman BM. Preference-based measurement of health-related quality of life (HRQL) in children with chronic musculoskeletal disorders (MSKDs). Med Decis Making. 2003 Jul-Aug; 23(4):314-22.
Score: 0.074
-
Naraine VS, Risebrough NA, Oh P, Blanchette VS, Lee S, Stain AM, Hedden D, Teitel JM, Feldman BM. Health-related quality-of-life treatments for severe haemophilia: utility measurements using the Standard Gamble technique. Haemophilia. 2002 Mar; 8(2):112-20.
Score: 0.067
-
Usuba K, Price VE, Blanchette V, Abad A, Altisent C, Buchner-Daley L, Carneiro JDA, Feldman BM, Fischer K, Grainger J, Holzhauer S, Luke KH, Meunier S, Ozelo M, Tang L, Antunes SV, Villaça P, Wakefield C, Wharfe G, Wu R, Young NL. Impact of prophylaxis on health-related quality of life of boys with hemophilia: An analysis of pooled data from 9 countries. Res Pract Thromb Haemost. 2019 Jul; 3(3):397-404.
Score: 0.055
-
Timmer MA, Gouw SC, Feldman BM, Zwagemaker A, de Kleijn P, Pisters MF, Schutgens REG, Blanchette V, Srivastava A, David JA, Fischer K, van der Net J. Measuring activities and participation in persons with haemophilia: A systematic review of commonly used instruments. Haemophilia. 2018 Mar; 24(2):e33-e49.
Score: 0.050
-
Carneiro JDA, Blanchette V, Ozelo MC, Antunes SV, Villaca PR, Young NL, Castro D, Brandão LR, Carcao M, Abad A, Feldman BM. Comparing the burden of illness of haemophilia between resource-constrained and unconstrained countries: the São Paulo-Toronto Hemophilia Study. Haemophilia. 2017 Sep; 23(5):682-688.
Score: 0.048
-
Fischer K, Poonnoose P, Dunn AL, Babyn P, Manco-Johnson MJ, David JA, van der Net J, Feldman B, Berger K, Carcao M, de Kleijn P, Silva M, Hilliard P, Doria A, Srivastava A, Blanchette V. Choosing outcome assessment tools in haemophilia care and research: a multidisciplinary perspective. Haemophilia. 2017 Jan; 23(1):11-24.
Score: 0.046
-
Villaça PR, Blanchette VS, Carneiro JD, Ozelo MC, Antunes S, Feldman BM, Abad A, Usuba K, Young NL. Validity of the Portuguese CHO-KLAT in Brazil. Haemophilia. 2016 Nov; 22(6):894-897.
Score: 0.046
-
Poonnoose PM, Hilliard P, Doria AS, Keshava SN, Gibikote S, Kavitha ML, Feldman BM, Blanchette V, Srivastava A. Correlating clinical and radiological assessment of joints in haemophilia: results of a cross sectional study. Haemophilia. 2016 Nov; 22(6):925-933.
Score: 0.046
-
van den Berg HM, Feldman B, Fischer K, Blanchette VS, Poonnoose P, Srivastava A. Reply to the letter of O'Mahoney et al.: Patient-reported outcome is not confined to HRQOL. Haemophilia. 2016 05; 22(3):e209-11.
Score: 0.045
-
Berger KC, Feldman BM, Wasserman J, Schramm W, Blanchette V, Fischer K. Securing reimbursement for patient centered haemophilia care: major collaborative efforts are needed. Haematologica. 2016 Mar; 101(3):266-8.
Score: 0.045
-
van den Berg HM, Feldman BM, Fischer K, Blanchette V, Poonnoose P, Srivastava A. Assessments of outcome in haemophilia - what is the added value of QoL tools? Haemophilia. 2015 Jul; 21(4):430-5.
Score: 0.042
-
Abrahamyan L, Willan AR, Beyene J, Mclimont M, Blanchette V, Feldman BM. Using value-of-information methods when the disease is rare and the treatment is expensive--the example of hemophilia A. J Gen Intern Med. 2014 Aug; 29 Suppl 3:S767-73.
Score: 0.040
-
Sun J, Hilliard PE, Feldman BM, Zourikian N, Chen L, Blanchette VS, Luke KH, Poon MC. Chinese Hemophilia Joint Health Score 2.1 reliability study. Haemophilia. 2014 May; 20(3):435-40.
Score: 0.038
-
Kraft J, Blanchette V, Babyn P, Feldman B, Cloutier S, Israels S, Pai M, Rivard GE, Gomer S, McLimont M, Moineddin R, Doria AS. Magnetic resonance imaging and joint outcomes in boys with severe hemophilia A treated with tailored primary prophylaxis in Canada. J Thromb Haemost. 2012 Dec; 10(12):2494-502.
Score: 0.036
-
Miles BS, Anderson P, Agostino A, Golomb MR, Achonu C, Blanchette V, Feldman BM, McLimont M, Revel-Vilk S, Stain A, Barnes MA. Effect of intracranial bleeds on the neurocognitive, academic, behavioural and adaptive functioning of boys with haemophilia. Haemophilia. 2012 Mar; 18(2):229-34.
Score: 0.033
-
Groen W, van der Net J, Bos K, Abad A, Bergstrom BM, Blanchette VS, Feldman BM, Funk S, Helders P, Hilliard P, Manco-Johnson M, Petrini P, Zourikian N, Fischer K. Joint health and functional ability in children with haemophilia who receive intensive replacement therapy. Haemophilia. 2011 Sep; 17(5):783-90.
Score: 0.032
-
Hang MX, Blanchette VS, Pullenayegum E, McLimont M, Feldman BM. Age at first joint bleed and bleeding severity in boys with severe hemophilia A: Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost. 2011 May; 9(5):1067-9.
Score: 0.032
-
Heemstra HE, Zwaan T, Hemels M, Feldman BM, Blanchette V, Kern M, Einarson TR. Cost of severe haemophilia in Toronto. Haemophilia. 2005 May; 11(3):254-60.
Score: 0.021
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|